Trends in drug-resistant tuberculosis in a gold-mining workforce in South Africa, 2002-2008

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 7, 2012, Pages 967-973

  Van Halsema, Clare L ^a   Fielding, K L ^a   Chihota, V N ^b   Lewis, J J ^a   Churchyard, G J ^a,b,c   Grant, A D ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b AURUM INSTITUTE   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Drug susceptibility testing; HIV; Isoniazid; Multidrug resistance; Rifampicin

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DATA MINING; DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SOUTH AFRICA;

ADULT; ANTITUBERCULAR AGENTS; GOLD; HIV INFECTIONS; HUMANS; ISONIAZID; MIDDLE AGED; MINING; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RIFAMPIN; RISK FACTORS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84862189584     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0122     Document Type: Article

References (26)

1. Corbett E L, Churchyard G J, Charalambous S, et al. Morbidity and mortality in South African gold miners; impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 32: 1251-1258. (Pubitemid 34450674)
2. World Health Organization. Global tuberculosis control: WHO report. WHO/HTM/TB/2010.07. 2010. Geneva, Switzerland: WHO, 2010.
3. Lewis J J, Charalambous S, Day J H, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 2009; 180: 1271-1278.
4. Corbett E L, Churchyard G J, Clayton T C, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14: 2759-2768. (Pubitemid 32118730)
5. Churchyard G J, Corbett E L, Kleinschmidt I, Mulder D, De Cock K M. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis 2000; 4: 433-440. (Pubitemid 30256846)
6. Murray J, Sonnenberg P, Shearer S, Godfrey-Faussett P. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection. S Afr Med J 2000; 90: 381-386. (Pubitemid 30303556)
7. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
8. Calver A D, Falmer A A, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010; 16: 264-271.
9. Fielding K L, Grant A D, Hayes R J, Chaisson R E, Corbett E L, Churchyard G J. Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis among gold miners in South Africa. Contemp Clin Trials 2011; 32: 382-392.
10. World Health Organization. Anti-tuberculosis drug resistance in the world. 4th global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
11. Chudeya S, Winston C A, Peloquin C A, et al. Isoniazid, rifampicin, ethambutol and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48: 1685-1694.
12. Srivastava S, Pasipanodya J G, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1959.
13. Godfrey-Faussett P, Sonnenberg P, Shearer S C, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000; 356: 1066-1071.
14. Van Rie A, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 2000; 356: 22-25. (Pubitemid 30416990)
15. Weyer K, Lancaster J, Brand J, van der Walt M, Levin J. Survey of tuberculosis drug resistance in South Africa 2001-2002. Cape Town, South Africa: Medical Research Council, 2004. http://www.sahealthinfo.org/tb/tbsurvey.htm Accessed March 2012.
16. Suchindran S, Brouwer E S, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 2009; 4: e5561.
17. Lawn S D, Myer L, Edwards D, Bekker L G, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-1725.
18. Abdool Karim S S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
19. Blanc F X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Eng J Med 2011; 365: 1471-1481.
20. Havlir D V, Kendall M A, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Eng J Med 2011; 365: 1482-1491.
21. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva, Switzerland: WHO, 2010.
22. Seung K J, Omatayo D B, Keshavjee S, Furin J J, Farmer P E, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa. PLoS One 2009; 4: e7186.
23. Hassim S, Shaw P A, Sangweni P, et al. Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis 2010; 50: 1053-1059.
24. Gandhi N R, Shah N S, Andrews J R, et al. HIV co-infection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2009; 181: 80-86.
25. van Halsema C L, Fielding K L, Chihota V N, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010; 24: 1051-1055.
26. Balcells M E, Thomas S L, Godfrey-Faussett P, Grant A D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751. (Pubitemid 43726847)